Key result
Combining glycoprotein IIb/IIIa receptor antagonists with thrombolytics is an investigational strategy aimed at improving outcomes in patients with acute myocardial infarction.
Why the study?
Does combining glycoprotein IIb/IIIa receptor antagonists with thrombolytics improve outcomes in patients with acute myocardial infarction?
Does combining glycoprotein IIb/IIIa receptor antagonists with thrombolytics improve outcomes in patients with acute myocardial infarction?
This paper discusses the investigational strategy of combining glycoprotein IIb/IIIa receptor antagonists with thrombolytics to improve outcomes in acute myocardial infarction.
Rupture of an atherosclerotic plaque in a coronary artery with subsequent thrombosis is the cause of most acute myocardial infarctions. Thrombolytics are the standard pharmacologic agents used to restore normal blood flow through the occluded coronary artery. While the use of thrombolytics has decreased both short-term and long-term mortality in patients presenting with acute myocardial infarction, these agents do have limitations. Combining glycoprotein IIb/IIIa receptor antagonists with thrombolytics is one strategy being investigated to try to improve outcomes after acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Stephanie M. Inverso (2002) conducted a review in Acute Myocardial Infarction. Glycoprotein IIb/IIIa receptor antagonists combined with thrombolytics was evaluated. Combining glycoprotein IIb/IIIa receptor antagonists with thrombolytics is an investigational strategy aimed at improving outcomes in patients with acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: